(Q52638749)

5 May 2018

title

Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash. (English)

1 reference

5 May 2018

0 references

F L Wright

1

1 reference

5 May 2018

R J Rodgers

series ordinal

2

1 reference

5 May 2018

publication date

1 March 2013

1 reference

5 May 2018

published in

Psychopharmacology

1 reference

5 May 2018

volume

228

1 reference

5 May 2018

issue

2

1 reference

5 May 2018

page(s)

291-307

1 reference

5 May 2018

https://scigraph.springernature.com/pub.10.1007/s00213-013-3036-6

exact match

0 references

cites work

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

'Liking' and 'wanting' food rewards: brain substrates and roles in eating disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

The tempted brain eats: pleasure and desire circuits in obesity and eating disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Behavioural structure and mechanisms of anorexia: calibration of natural and abnormal inhibition of eating.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Endogenous opioids and feeding behavior: a 30-year historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Effects of acute administration of bupropion on behavior in the elevated plus-maze test by NMRI mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Naloxonazine, a specific mu-opioid receptor antagonist, attenuates the increment of locomotor activity induced by acute methamphetamine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Effects of naltrexone on food preference and concurrent behavioral responses in food-deprived rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Cocaine: a microstructural analysis of its effects on feeding and associated behaviour in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Cannabinoids, opioids and eating behavior: the molecular face of hedonism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Effects of bupropion, alone or coadministered with nicotine, on social behavior in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Rational design of a combination medication for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Opioid receptor involvement in food deprivation-induced feeding: evaluation of selective antagonist and antisense oligodeoxynucleotide probe effects in mice and rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Pharmacological management of appetite expression in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

CNS regulation of appetite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

What is the prognosis for new centrally-acting anti-obesity drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Effects of systematic variation in presatiation and fasting on the behavioural satiety sequence in male rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Are delta-opioid receptors involved in the regulation of food and water intake?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Involvement of endogenous enkephalins in the feeding response to diazepam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Effect of naloxone and naltrexone on the development of satiation measured in the runway: comparisons with d-amphetamine and d-fenfluramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Effects of naloxone and naltrexone on meal patterns of freely-feeding rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Differential effects of CGS 8216 and naltrexone on ingestional behaviour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Comparison of the thermogenic and hypophagic effects of sibutramine's metabolite 2 and other monoamine reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Central and peripheral contributions of endogenous opioid systems to nutrient selection in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Bupropion effects on aggressiveness and anxiety in OF1 male mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Effects of acute bupropion administration on locomotor activity in adolescent and adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Behavioural satiety sequence (BSS): separating wheat from chaff in the behavioural pharmacology of appetite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Anti-obesity drugs: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

"Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

A comparison of the effects of opiate antagonists on operant and ingestive behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Rate-dependent effects of bupropion on nicotine self-administration and food-maintained responding in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Behaviourally-selective hypophagic effects of naloxone in non-deprived male rats presented with palatable food.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Effects of acute low-dose combined treatment with naloxone and AM 251 on food intake, feeding behaviour and weight gain in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Night and day: diurnal differences in the behavioural satiety sequence in male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Brain and serum levels of naloxone following peripheral administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Animal models to explore the effects of CNS drugs on food intake and energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

The utility of animal models to evaluate novel anti-obesity agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

How does bupropion work as a smoking cessation aid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

μ-Opioid receptors in the nucleus accumbens shell region mediate the effects of amphetamine on inhibitory control but not impulsive choice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Opioid peptides and the control of human ingestive behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Brainstem sensing of meal-related signals in energy homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Anorectic and behavioural effects of bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3036-6

Behavioral effects of separate and combined administration of naloxone and d-amphetamine

21 January 2018

1 reference

12 December 2020

Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs

1 reference

12 December 2020

Bupropion hydrochloride ((±) α-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent

1 reference

12 December 2020

TOLERANCE TO AND PHYSICAL DEPENDENCE ON MORPHINE IN RATS

1 reference

12 December 2020

Naltrexone suppresses hyperphagia induced in the rat by a highly palatable diet

1 reference

12 December 2020

Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity

1 reference

12 December 2020

Studies of bupropion's mechanism of antidepressant activity

1 reference

12 December 2020

Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats.

1 reference

12 December 2020

Locomotor activity and anorexogenic action

1 reference

12 December 2020

Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo

1 reference

12 December 2020

Dual action of naloxone on feeding revealed by behavioural analysis: separate effects on initiation and termination of eating.

1 reference

12 December 2020

Bupropion induces sniffing: a possible dopaminergic mechanism

1 reference

12 December 2020

Bupropion: a review of its mechanism of antidepressant activity.

1 reference

12 December 2020

Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors.

1 reference

12 December 2020

Multiple opioid receptors: ligand selectivity profiles and binding site signatures

1 reference

12 December 2020

Bupropion is a nicotinic antagonist.

1 reference

12 December 2020

Why isn't bupropion the most frequently prescribed antidepressant?

1 reference

12 December 2020

10.1007/S00213-013-3036-6

Identifiers

DOI

1 reference

5 May 2018

PubMed ID

23455599

1 reference

5 May 2018